The Groundbreaking Treatment

In a medical breakthrough, 82-year-old oncologist Philip Salem has combined immunotherapy, chemotherapy, and targeted therapy to create a breakthrough cancer treatment called ICTriplex at his renowned Salem Oncology Center. The treatment has proven to achieve complete remission in 50 percent of patients, a success rate significantly higher than that of conventional treatments, which achieve less than 30 percent remission rate.

Revolutionizing Cancer Medicine

‘I have been in cancer medicine for 55 years. I have never seen before what I’m seeing now as a result of ICTriplex,’ Salem told ABC7. His research, published in the American Society of Clinical Oncology Journal in June 2022, has drawn desperate patients from around the world to Houston, Texas, seeking hope and the possibilities offered by this groundbreaking treatment.

Salem took an innovative approach by combining immunotherapy, chemotherapy, and targeted therapy, achieving complete remission in 50 to 60 percent of patients with a wide spectrum of cancer diagnoses. Patients, even those who were told by major cancer centers to go home and die, have experienced the profound impact of this treatment.

A Potential Lifeline

Bianca Gurrado, a patient who traveled from Italy to Houston, experienced the effectiveness of the treatment firsthand. After her cancer was advancing and spreading, Gurrado began therapy in Italy, but it did not produce favorable results. However, with treatment from Salem, she is now in a state of complete remission, offering her renewed hope and second chance at life.

The groundbreaking treatment, known as ICTriplex, has shown remarkable efficacy in various forms of cancer, including lung, pancreatic, colorectal, and breast cancer. Salem’s research involving 41 patients at an advanced stage of disease progression yielded an impressive total remission rate of 90 percent, considering patients in both partial remission and complete remission.

A Beacon of Hope

As a beacon of hope in the battle against cancer, Salem’s treatment has transformed the lives of many patients. Patients, such as Ellie Moore, diagnosed with stage 4 lung cancer a decade ago, have achieved remission and continue to lead fulfilling lives. Moore attributes her success to Salem’s determination and innovative approach to treatment.

Salem’s treatment, considered a first-line therapy, has been particularly effective in lung and pancreatic cancer patients, achieving a remarkable complete remission rate of 70 percent. With such groundbreaking success, there is newfound hope for cancer patients who were previously left with limited treatment options.

A New Era in Cancer Treatment’

As cancer treatment shifts towards a more personalized approach, Salem’s innovative method is paving the way for a new era in cancer care. The combination of immunotherapy, chemotherapy, and targeted therapy has the potential to revolutionize the treatment of advanced cancer, opening doors for patients who have been given limited prospects.

Cancer patient Marco Praagman, acknowledging the significant difference in treatment outcomes, expressed, ‘It’s an easy choice when you have zero percent chance versus a 50 percent chance.’ The impact of Salem’s groundbreaking treatment cannot be understated, as it offers renewed hope to cancer patients worldwide.

Conclusion

Through a combination of dedication, experience, and an innovative treatment approach, Philip Salem, a renowned oncologist at the Salem Oncology Center in Houston, has created a groundbreaking cancer treatment called ICTriplex, which achieves an incredible 50 percent remission rate. With patients from all corners of the globe seeking Salem’s expertise, the impact of this treatment cannot be overstated. As the field of cancer medicine continues to evolve, Salem’s research and remarkable results serve as a beacon of hope for those battling this devastating disease.